Connect
MJA
MJA

Coexisting chronic obstructive pulmonary disease and cardiovascular disease in clinical practice: a diagnostic and therapeutic challenge

Paul Leong, Martin I Macdonald, Brian S Ko and Phil G Bardin
Med J Aust 2019; 210 (9): . || doi: 10.5694/mja2.50120
Published online: 8 April 2019

Summary

  • Chronic obstructive pulmonary disease (COPD) and cardiovascular disease (CVD) frequently coexist but combined disease is often not recognised. Since symptoms overlap significantly, it is common for patients’ presentations to be attributed to one disease alone, and for the other to be overlooked.
  • The effect of COPD and CVD goes beyond the shared risk factors of smoking and advancing age. The presence of COPD adversely affects cardiac disease and vice versa. In comparison to individuals with one disease alone, those with both conditions have a higher mortality rate, experience more frequent exacerbations with more hospitalisations and have worse quality of life.
  • More patients with mild and moderate COPD die from CVD than from COPD, and there is a higher rate of arrhythmias, particularly atrial fibrillation. Accurate and timely diagnosis is therefore crucial.
  • Retrospective evidence indicates that individuals with COPD and CVD may have better outcomes with appropriate CVD pharmacotherapy, yet robust prospective evidence is lacking. Inhaled medications for patients with stable COPD improve quality of life and reduce exacerbations, but there is limited evidence that they reduce mortality.
  • A low threshold for investigation and treatment of CVD in COPD and COPD in CVD is essential.

  • 1 Monash Lung and Sleep, Monash Health, VIC
  • 2 Monash Heart, Monash Health, VIC


Correspondence: paul.leong@monash.edu

Acknowledgements: 

This work was supported by a National Health and Medical Research Council Postgraduate Scholarship.

Competing interests:

No relevant disclosures.

  • 1. Global Initiative for Chronic Obstructive Lung Disease. Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease. GOLD, 2017. https://goldcopd.org/wp-content/uploads/2017/11/GOLD-2018-v6.0-FINAL-revised-20-Nov_WMS.pdf (viewed Dec 2017).
  • 2. Yang I, Dabscheck E, George J, et al. The COPD‐X plan: Australian and New Zealand guidelines for the management of chronic obstructive pulmonary disease 2017. Version 2.52 (December 2017). Brisbane: Lung Foundation Australia, 2017. https://copdx.org.au/wp-content/uploads/2018/03/COPDX-V2-52-Dec-2017_2.pdf (viewed Mar 2018).
  • 3. Australian Institute of Health and Welfare. Admitted patient care 2015–16: Australian hospital statistics (Health Services Series No. 75; Cat. No. HSE 185). Canberra: AIHW, 2017. https://www.aihw.gov.au/reports/hospitals/ahs-2015-16-admitted-patient-care/contents/table-of-contents (viewed Mar 2018).
  • 4. Britt H, Miller GC, Henderson J, et al. General practice activity in Australia 2015–16. Sydney: Sydney University Press, 2016. https://ses.library.usyd.edu.au/bitstream/2123/15514/5/9781743325148_ONLINE.pdf (viewed Mar 2018).
  • 5. Chen W, Thomas J, Sadatsafavi M, FitzGerald JM. Risk of cardiovascular comorbidity in patients with chronic obstructive pulmonary disease: a systematic review and meta‐analysis. Lancet Respir Med 2015; 3: 631–639.
  • 6. Morgan AD, Zakeri R, Quint JK. Defining the relationship between COPD and CVD: what are the implications for clinical practice? Ther Adv Respir Dis 2018; 12: 175346581775052.
  • 7. Brekke PH, Omland T, Smith P, Søyseth V. Underdiagnosis of myocardial infarction in COPD – Cardiac Infarction Injury Score (CIIS) in patients hospitalised for COPD exacerbation. Respir Med 2008; 102: 1243–1247.
  • 8. Barnes PJ. Senescence in COPD and Its Comorbidities. Annu Rev Physiol 2017; 79: 517–539.
  • 9. Roversi S, Fabbri LM, Sin DD, et al. Chronic obstructive pulmonary disease and cardiac diseases: an urgent need for integrated care. Am J Respir Crit Care Med 2016; 194: 1319–1336.
  • 10. Wang L, Zhu Y, Cui J, et al. Subclinical atherosclerosis risk markers in patients with chronic obstructive pulmonary disease: A systematic review and meta‐analysis. Respir Med 2017; 123: 18–27.
  • 11. Zagaceta J, Bastarrika G, Zulueta JJ, et al. Prospective comparison of non‐invasive risk markers of major cardiovascular events in COPD patients. Respir Res 2017; 18: 175.
  • 12. Gaisl T, Schlatzer C, Schwarz EI, et al. Coronary artery calcification, epicardial fat burden, and cardiovascular events in chronic obstructive pulmonary disease. PLOS One 2015; 10: e0126613.
  • 13. Feary JR, Rodrigues LC, Smith CJ, et al. Prevalence of major comorbidities in subjects with COPD and incidence of myocardial infarction and stroke: a comprehensive analysis using data from primary care. Thorax 2010; 65: 956–962.
  • 14. Rothnie KJ, Yan R, Smeeth L, Quint JK. Risk of myocardial infarction (MI) and death following MI in people with chronic obstructive pulmonary disease (COPD): a systematic review and meta‐analysis. BMJ Open 2015; 5: e007824.
  • 15. Wakabayashi K, Gonzalez MA, Delhaye C, et al. Impact of chronic obstructive pulmonary disease on acute‐phase outcome of myocardial infarction. Am J Cardiol 2010; 106: 305–309.
  • 16. Andell P, Koul S, Martinsson A, et al. Impact of chronic obstructive pulmonary disease on morbidity and mortality after myocardial infarction. Open Heart 2014; 1: e000002.
  • 17. Jatene T, Biering‐Sørensen T, Nochioka K, et al. Frequency of cardiac death and stent thrombosis in patients with chronic obstructive pulmonary disease undergoing percutaneous coronary intervention (from the BASKET‐PROVE I and II Trials). Am J Cardiol 2017; 119: 14–19.
  • 18. Lahousse L, Tiemeier H, Ikram MA, Brusselle GG. Chronic obstructive pulmonary disease and cerebrovascular disease: a comprehensive review. Respir Med 2015; 109: 1371–1380.
  • 19. Houben‐Wilke S, Jörres RA, Bals R, et al. peripheral artery disease and its clinical relevance in patients with chronic obstructive pulmonary disease in the COPD and Systemic Consequences‐Comorbidities Network Study. Am J Respir Crit Care Med 2017; 195: 189–197.
  • 20. Sidney S, Sorel M, Quesenberry CP, et al. COPD and incident cardiovascular disease hospitalizations and mortality: Kaiser Permanente Medical Care Program. Chest 2005; 128: 2068–2075.
  • 21. Huiart L, Ernst P, Suissa S. Cardiovascular Morbidity and Mortality in COPD. Chest 2005; 128: 2640–2646.
  • 22. Goudis CA. Chronic obstructive pulmonary disease and atrial fibrillation: an unknown relationship. J Cardiol 2017; 69: 699–705.
  • 23. Konecny T, Somers KR, Park JY, et al. Chronic obstructive pulmonary disease as a risk factor for ventricular arrhythmias independent of left ventricular function. Heart Rhythm 2018; 15: 832–838.
  • 24. Curkendall SM, deLuise C, Jones JK, et al. Cardiovascular disease in patients with chronic obstructive pulmonary disease, Saskatchewan Canada. Ann Epidemiol 2006; 16: 63–70.
  • 25. De Blois J, Simard S, Atar D, Agewall S. COPD predicts mortality in HF: the Norwegian Heart Failure Registry. J Card Fail 2010; 16: 225–229.
  • 26. Macchia A, Rodriguez Moncalvo JJ, Kleinert M, et al. Unrecognised ventricular dysfunction in COPD. Eur Respir J 2012; 39: 51–58.
  • 27. Mannino DM, Thorn D, Swensen A, Holguin F. Prevalence and outcomes of diabetes, hypertension and cardiovascular disease in COPD. Eur Respir J 2008; 32: 962–969.
  • 28. Terzano C, Romani S, Conti V, et al. Atrial fibrillation in the acute, hypercapnic exacerbations of COPD. Eur Rev Med Pharmacol Sci 2014; 18: 2908–2917.
  • 29. Tribouilloy C, Rusinaru D, Mahjoub H, et al. Prognosis of heart failure with preserved ejection fraction: a 5 year prospective population‐based study. Eur Heart J 2008; 29: 339–347.
  • 30. Chaouat A, Naeije R, Weitzenblum E. Pulmonary hypertension in COPD. Eur Respir J 2008; 32: 1371–1385.
  • 31. Hoeper MM, Humbert M, Souza R, et al. A global view of pulmonary hypertension. Lancet Respir Med 2016; 4: 306–322.
  • 32. Hoeper MM, McLaughlin VV, Dalaan AMA, et al. Treatment of pulmonary hypertension. Lancet Respir Med 2016; 4: 323–336.
  • 33. MacDonald MI, Shafuddin E, King PT, et al. Cardiac dysfunction during exacerbations of chronic obstructive pulmonary disease. Lancet Respir Med 2016; 4: 138–148.
  • 34. Chang CL, Robinson SC, Mills GD, et al. Biochemical markers of cardiac dysfunction predict mortality in acute exacerbations of COPD. Thorax 2011; 66: 764–768.
  • 35. Pizarro C, Herweg‐Steffens N, Buchenroth M, et al. Invasive coronary angiography in patients with acute exacerbated COPD and elevated plasma troponin. Int J Chron Obstruct Pulmon Dis 2016; 11: 2081–2089.
  • 36. Rutten FH, Moons KGM, Cramer M‐JM, et al. Recognising heart failure in elderly patients with stable chronic obstructive pulmonary disease in primary care: cross sectional diagnostic study. BMJ 2005; 331: 1379.
  • 37. Liang J, Abramson MJ, Zwar NA, et al. Diagnosing COPD and supporting smoking cessation in general practice: evidence‐practice gaps. Med J Aust 2018; 208: 29–34. https://www.mja.com.au/journal/2018/208/1/diagnosing-copd-and-supporting-smoking-cessation-general-practice-evidence
  • 38. Hole DJ, Watt GCM, Davey‐Smith G, et al. Impaired lung function and mortality risk in men and women: findings from the Renfrew and Paisley prospective population study. BMJ 1996; 313: 711–715.
  • 39. Wannamethee SG, Shaper AG, Papacosta O, et al. Lung function and airway obstruction: associations with circulating markers of cardiac function and incident heart failure in older men—the British Regional Heart Study. Thorax 2016; 71: 526–534.
  • 40. Storey P. Imaging for cardiac disease: a practical guide for general practitioners. Aust Fam Physician 2014; 43: 260–263.
  • 41. Wright SP, Doughty RN, Pearl A, et al. Plasma amino‐terminal pro‐brain natriuretic peptide and accuracy of heart‐failure diagnosis in primary care. J Am Coll Cardiol 2003; 42: 1793–1800.
  • 42. Hackshaw A, Morris JK, Boniface S, et al. Low cigarette consumption and risk of coronary heart disease and stroke: meta‐analysis of 141 cohort studies in 55 study reports. BMJ 2018; 360: j5855.
  • 43. Australian Technical Advisory Group on Immunisation. The Australian Immunisation Handbook. Canberra: Australian Government Department of Health, 2018. https://immunisationhandbook.health.gov.au/ (viewed Mar 2019).
  • 44. Puhan MA, Scharplatz M, Troosters T, Steurer J. Respiratory rehabilitation after acute exacerbation of COPD may reduce risk for readmission and mortality — a systematic review. Respir Res 2005; 6: 54.
  • 45. Rothnie KJ, Smeeth L, Herrett E, et al. Closing the mortality gap after a myocardial infarction in people with and without chronic obstructive pulmonary disease. Heart 2015; 101: 1103–1110.
  • 46. Lahousse L, Verhamme KM, Stricker BH, Brusselle GG. Cardiac effects of current treatments of chronic obstructive pulmonary disease. Lancet Respir Med 2016; 4: 149–164.
  • 47. Suissa S. Co‐morbidity in COPD: the effects of cardiovascular drug therapies. Respiration 2010; 80: 3–7.
  • 48. Pavasini R, Biscaglia S, d'Ascenzo F, et al. Antiplatelet treatment reduces all‐cause mortality in COPD patients: a systematic review and meta‐analysis. J Chronic Obstr Pulm Dis 2016; 13: 509–514.
  • 49. Goto T, Faridi MK, Camargo CA, Hasegawa K. The association of aspirin use with severity of acute exacerbation of chronic obstructive pulmonary disease: a retrospective cohort study. npj Prim Care Respir Med 2018; 28: 7.
  • 50. Lawes CM, Thornley S, Young R, et al. Statin use in COPD patients is associated with a reduction in mortality: a national cohort study. Prim Care Respir J 2012; 21: 35–40.
  • 51. Criner GJ, Connett JE, Aaron SD, et al. Simvastatin for the prevention of exacerbations in moderate‐to‐severe COPD. N Engl J Med 2014; 370: 2201–2210.
  • 52. Zhang W, Zhang Y, Li C‐W, et al. Effect of Statins on COPD. Chest 2017; 152: 1159–1168.
  • 53. Parikh MA, Aaron CP, Hoffman EA, et al. Angiotensin‐converting inhibitors and angiotensin II receptor blockers and longitudinal change in percent emphysema on computed tomography. the Multi‐Ethnic Study of Atherosclerosis Lung Study. Ann Am Thorac Soc 2017; 14: 649–658.
  • 54. Mortensen EM, Copeland LA, Pugh MJV, et al. Impact of statins and ACE inhibitors on mortality after COPD exacerbations. Respir Res 2009; 10: 45.
  • 55. Mancini GBJ, Etminan M, Zhang B, et al. Reduction of morbidity and mortality by statins, angiotensin‐converting enzyme inhibitors, and angiotensin receptor blockers in patients with chronic obstructive pulmonary disease. J Am Coll Cardiol 2006; 47: 2554–2560.
  • 56. Salpeter SR, Ormiston TM, Salpeter EE. Cardioselective beta‐blockers for chronic obstructive pulmonary disease. Cochrane Database Syst Rev 2005; (4): CD003566.
  • 57. Lipworth B, Wedzicha J, Devereux G, et al. Beta‐blockers in COPD: time for reappraisal. Eur Respir J 2016; 48: 880–888.
  • 58. van Gestel YRBM, Hoeks SE, Sin DD, Welten GMJM, et al. Impact of cardioselective β‐blockers on mortality in patients with chronic obstructive pulmonary disease and atherosclerosis. Am J Respir Crit Care Med 2008; 178: 695–700.
  • 59. Bhatt SP, Connett JE, Voelker H, et al. β‐Blockers for the prevention of acute exacerbations of chronic obstructive pulmonary disease (βLOCK COPD): a randomised controlled study protocol. BMJ Open 2016; 6: e012292.
  • 60. Vestbo J, Anderson JA, Brook RD, et al. Fluticasone furoate and vilanterol and survival in chronic obstructive pulmonary disease with heightened cardiovascular risk (SUMMIT): a double‐blind randomised controlled trial. Lancet 2016; 387: 1817–1826.
  • 61. Calverley PMA, Anderson JA, Celli B, et al. Salmeterol and fluticasone propionate and survival in chronic obstructive pulmonary disease. N Engl J Med 2007; 356: 775–789.
  • 62. Celli B, Decramer M, Kesten S, et al. Mortality in the 4‐year trial of tiotropium (UPLIFT) in patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2009; 180: 948–955.
  • 63. Celli B, Decramer M, Leimer I, et al. Cardiovascular safety of tiotropium in patients with COPD. Chest 2010; 137: 20–30.
  • 64. Calverley PMA, Anderson JA, Celli B, et al. Cardiovascular events in patients with COPD: TORCH Study results. Thorax 2010; 65: 719–725.
  • 65. Lipson DA, Barnhart F, Brealey N, et al. Once‐daily single‐inhaler triple versus dual therapy in patients with COPD. N Engl J Med 2018; 378: 1671–1680.
  • 66. Rajwani A, Adam Z, Hall JA. Bronchogenic stress cardiomyopathy: a case series. Cardiology 2015; 130: 106–111.
  • 67. McDonald CF, Whyte K, Jenkins S, et al. Clinical practice guideline on adult domiciliary oxygen therapy: executive summary from the Thoracic Society of Australia and New Zealand. Respirology 2016; 21: 76–78.
  • 68. Heart Foundation. Clinical information. Resources for health professionals. https://www.heartfoundation.org.au/for-professionals/clinical-information (viewed Oct 2018).

Author

remove_circle_outline Delete Author
add_circle_outline Add Author

Comment
Do you have any competing interests to declare? *

I/we agree to assign copyright to the Medical Journal of Australia and agree to the Conditions of publication *
I/we agree to the Terms of use of the Medical Journal of Australia *
Email me when people comment on this article

Online responses are no longer available. Please refer to our instructions for authors page for more information.